The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

By R. Fechtner, N. Karunaratne, A. Khoury, T. Realini, Jianming Ren, M.D.T. Robison, George Shafranov, Gilbert Sussman, Mike Roy Willman, Thomas W. Uihlein and 6 more. A M A Archives of Ophthalmology, 2002

3,836 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/4a65c81106dc1681a79a81a4a86971978ed78ce1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Labbé
2. Hong Liang
3. A. Pauly
4. F. Brignole-Baudouin
5. M. Kass
6. M. Wilson
7. J. Beiser
8. J. Miller

Citations in the corpus

• Preservatives in eyedrops: the good, the bad and the ugly. (2010, background): “The Ocular Hypertension Treatment Study demonstrated that approximately 40% of patients initially diagnosed with ocular hypertension were using two drugs after 5 years, 9% three or more, with even higher rates in African-American patients (Kass et al., 2002).”
• The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. (2002, methodology): “The results of the OHTS are described in detail in our companion article.(1)”
• Glaucoma (2018, unknown): “One-half of patients with POAG have an intraocular pressure within the normal range, and most patients with elevated pressure (22 mm Hg or greater) do not develop glaucoma.(7,8,20) Further, intraocular pressure measurements vary diurnally.”